Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

NCT04265781 | Completed Phase 1

• 1 other identifier: 19738
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants. Study drug BAY1817080 is a drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins expressed on the sensory nerves of the womb tissue, bladder or airway which are oversensitive in the patients with endometriosis (a condition where the tissue that usually grows inside the womb grows outside of the womb), overactive bladder (a condition that causes a sudden urge to urinate often or more frequently) and long-standing cough with or without clear causes. Participants in this study will receive either the study drug or placebo tablets (a placebo looks like the test drug but does not have any medicine in it). The dosage will be either one single dose of study drug/placebo received on only one day or multiple doses of study drug/placebo received twice daily for 13 days plus one dose in the morning of the 14th day. The total study duration for each participant will be usually no more than 42 days. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.

Conditions

Endometriosis Related Pain; Overactive Bladder; Diabetic Neuropathic Pain; Refractory or Unexplained Chronic Cough

Keywords

Refractory or unexplained chronic cough; Healthy volunteers; P2X3 receptor antagonist

Outcome Measures

Primary Outcomes (4)

• Frequency of treatment-emergent adverse events (TEAE) after single dose of BAY1817080

  Up to 14 days

• Severity of treatment-emergent adverse events after single dose of BAY1817080

  Up to 14 days

• Frequency of treatment-emergent adverse events after multiple doses of BAY1817080

  Up to 27 days

• Severity of treatment-emergent adverse events after multiple doses of BAY1817080

  Up to 27 days

Secondary Outcomes (4)

• Maximum plasma concentration of BAY1817080 after single dose (Cmax)

  At 0 hour before study drug administration and up to 15 hours after study drug administration at Day 1 and at 0 hours on Day 2 to Day 10

• Area under the concentration-time curve of BAY1817080 after single dose (AUC)

  At 0 hour before study drug administration and up to 15 hours after study drug administration at Day 1 and at 0 hours on Day 2 to Day 10

• Maximum plasma concentration of BAY1817080 after multiple doses (Cmax,md)

  At 0 hours before drug administration and up to 12 hours after drug administration on Day 1, at 0 hours from Day 2 to Day 9 and from Day 11 to Day 12, at 0 and 12 hours on Day 13, at 0 hours until 15 hours on Day 14, and at 0 hours from Day 15 to Day 23

• Area under the concentration-time curve of BAY1817080 after multiple dose (AUCτ,md)

  At 0 hours before drug administration and up to 12 hours after drug administration on Day 1, at 0 hours from Day 2 to Day 9 and from Day 11 to Day 12, at 0 and 12 hours on Day 13, at 0 hours until 15 hours on Day 14, and at 0 hours from Day 15 to Day 23

Study Arms (4)

Dose escalation BAY1817080

EXPERIMENTAL

Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.

Drug: BAY1817080

Dose expansion BAY1817080

EXPERIMENTAL

Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.

Drug: BAY1817080

Dose escalation Placebo

PLACEBO COMPARATOR

Participants receive placebo tablets orally as a single dose on Day 1.

Drug: Matching Placebo

Dose expansion Placebo

PLACEBO COMPARATOR

Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.

Drug: Matching Placebo

Interventions

BAY1817080 DRUG

Three different doses over the course of study

Dose escalation BAY1817080; Dose expansion BAY1817080

Matching Placebo DRUG

Matching Placebo to BAY1817080

Dose escalation Placebo; Dose expansion Placebo

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participant must be 20 to 45 years of age inclusive, at the time of signing the informed consent.
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG.
• Non-smoker for at least 6 months and with a pack year history of equal to or less than 5 years
• Race: Japanese.
• BMI: above or equal 18.0 and below or equal 30.0 kg/m² at the screening visit.
• Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the ICF and 90 days after the last administration of study intervention.

You may not qualify if:

• Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
• Relevant diseases potentially interfering with the study objectives within the 4 weeks before screening or between screening and randomization
• Any febrile illness within the four weeks before screening or between screening and randomization
• Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies
• Known or suspected malignant tumors or carcinoma in situ
• Any history of malignant tumors
• Any known or suspected benign tumors of the liver and/or pituitary gland
• Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). Note: According to this criterion there must have been an interval of at least 6 months between the subsidence of any viral hepatitis (normalization of liver parameters) and the screening visit.

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Hakata Clinic

Fukuoka, 812-0025, Japan

Location

Related Publications (1)

• Li X, Haranaka M, Li H, Liu P, Chen H, Klein S, Reif S, Francke K, Friedrich C, Okumura K. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants. Clin Pharmacokinet. 2024 Jun;63(6):901-915. doi: 10.1007/s40262-024-01387-y. Epub 2024 Jun 21.

  PMID: 38907175 DERIVED

Related Links

• Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

MeSH Terms

Conditions

Urinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2020
• First Posted: February 12, 2020
• Study Start: February 15, 2020
• Primary Completion: September 20, 2020
• Study Completion: September 20, 2020
• Last Updated: January 26, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)